CD40 Ligand Market 2021 is Growing Vigorously in Pharma Sector with Prominent Vendors: Juno Therapeutics Inc., Targovax AS, XL-protein GmbH, ImmuNext, Inc., Bristol-Myers Squibb Company

CD40 Ligand Market Report provides detailed analysis of Growth Factors of the market as well as it gives an analysis of the Market size, Latest trends, SWOT Analysis by Regions and Forecasted market research data until 2026. The CD40 Ligand market report has studied key opportunities in the market and influencing factors which are useful to the business. The report also maps the qualitative and quantitative impact of various market factors like macro-economic indicators, PPP, Epidemiological data, Insurance scenario and patent and IP information, Government Policies and business regulations along market attractiveness as per segments.

The CD40 Ligand market revenue was 405 Million USD in 2019, and will reach 551 Million USD in 2025, with a CAGR of 5.26% during 2020-2025. 

Get Sample Copy Of This Report + All Related Graphs (Covid-19 Update):

https://www.marketinsightsreports.com/reports/05202907726/global-cd40-ligand-market-insights-impact-of-covid-19-and-future-expectations-to-2025/inquiry?source=Openpr&Mode=Twelve                                      

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global CD40 Ligand Market: Juno Therapeutics Inc., Targovax AS, XL-protein GmbH, ImmuNext, Inc., Bristol-Myers Squibb Company, Biogen, Inc., eTheRNA Immunotherapies NV, MedImmune, LLC and others.

The ligand of CD40, known as CD154 or CD40L, is a type II transmembrane protein, with a variable molecular weight between 32 and 39 kDa because of post-translation modifications. CD40L is a member of the TNF superfamily and is characterized by a sandwich extracellular structure that is composed of a -sheet, -helix loop, and a ?-sheet. CD40L is expressed primarily by activated T cells, as well as activated B cells and platelets; and under inflammatory conditions is also induced on monocytic cells, natural killer cells, mast cells, and basophils.

Industry News and Developments:

Targovax announces publication of new oncolytic virus data in the Journal of Medical Virology and Cancer Gene Therapy

September 12, 2018: Oslo, Norway, 12 September 2018 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, is pleased to note that pre-clinical data from its ONCOS oncolytic virus program has been published in two leading, peer reviewed publications, the Journal of Medical Virology and Cancer Gene Therapy.

The first paper, entitled “Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model” was published in the Journal of Medical Virology, [Vol 90:1669–1673, date 24 May 2018]. This paper demonstrates that Targovax’s oncolytic virus, ONCOS-102, induces T-cells specific to the tumor associated antigen (TAA) mesothelin in a mesothelioma mouse model. Mesothelin is overexpressed in many types of cancer, and particularly frequently in mesothelioma. This result provides an important in vivo mechanistic proof that ONCOS-102 can generate a directed T-cell response towards a well-known TAA. The paper can be found here.

The second paper, entitled “Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401” was published in Cancer Gene Therapy on 30 July 2018. This paper describes one of Targovax’s pre-clinical oncolytic viruses, ONCOS-401, which carries a transgene for CD40-ligand (CD40L), an important signalling molecule activating a wide range of immune and inflammatory responses. The study shows that ONCOS-401 produces functional CD40L, and also describes a rapid and simple assay to quantify the efficacy of CD40L production in vitro. The abstract can be found here.

Sanofi licences ImmuNext autoimmune disease drug

16th January 2017: ImmuNext will grant Sanofi an exclusive, worldwide license to develop and commercialise INX-021, a CD40L monoclonal antibody in preclinical development that suppresses the activity of a cellular pathway that is overactive in many autoimmune diseases, as the firm strives to expand its speciality care products.

As per the terms of the deal, both parties will also initiate a research collaboration to support clinical trials of the drug. ImmuNext could bank $500 million in milestone payments, as well as tiered royalties up to double digits on sales of products.

Global CD40 Ligand Market Split by Product Type and Applications:

On the basis of Types, the market is segmented into:

ISF-35
LOAd-700
MEDI-4920
MegaCD40L
Others

On the basis of Application, the market is segmented into:

Autoimmune indications
Hepatitis B
Bladder Cancer
Liver Cancer
Ovarian Cancer
Others

Buy The CD40 Ligand Market Report:
https://www.marketinsightsreports.com/report/purchase/05202907726?mode=su?source=Openpr&Mode=Twelve                  

Regional analysis:

This report covers South America, North America, Europe, Asia Pacific (APAC), Africa and The Middle East, taking into account the clear evidence of where the market is fully examined, typical market examples, blocks and open access roads for power generation. With a huge population, Asia Pacific has revenues in the picture year, and dominates the CD40 Ligand market share, at any given time. Continuous GDP reform; Institutional progress per capita is becoming urbanized in the metropolitan area. This expanded revenue has led to indulging in top private and unrealistic usage models in the CD40 Ligand market deployed in the region. While an important piece of the CD40 Ligand market center around the global expansion of business, territories such as the Middle East and Africa will grow steadily. Big market development will take place in Latin America because of the small expansion producers' attempts at profits. In Europe, a lethargic improvement is expected due to mood-oriented rules and early stages.

Key Points of CD40 Ligand Market Table of Contents:

-Market Overview: The report begins with this section where a product overview and key content on the product and application segments of the global CD40 Ligand market are provided. The highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

-Competition by company: Here we analyze the competition of the global CD40 Ligand market, by company price, revenue, sales and market share, market share, competitive landscape, and latest trends, mergers, expansions, acquisitions, and market share of top companies.

-Company Profile and Sales Data: As the name suggests, this section provides sales data and useful information about the business of key players in the global CD40 Ligand market. It describes the key businesses of gross margin, price, revenue, products and specifications, types, applications, competitors, manufacturing base, and key players operating in the global CD40 Ligand market.

-Market Forecast: Here the report provides a full forecast for the global CD40 Ligand market by product, application, and region. It also provides global sales and revenue forecasts for all years in the forecast period.

-Research Results and Conclusion: One of the last sections of the report where analyst findings and findings are provided.

What are the new revenue channels which companies can explore for growth?       

For More Information On This Report, Please Visit: https://www.marketinsightsreports.com/reports/05202907726/global-cd40-ligand-market-insights-impact-of-covid-19-and-future-expectations-to-2025?source=Openpr&Mode=Twelve                                   

Due to the onset of COVID-19 pandemic, several economies across the world have experienced harsh economic downturn. The industrialists across North America, Europe, Asia Pacific, Latin America and Middle East and Africa were facing problems due to changing preferences of the customers and demand fluctuation. The market research report covers pre-Covid-19 data for the CD40 Ligand market in years 2018 and 2020. Further, the report also covers forecast Covid-19 data from 2021 to 2026, which provides future outlook of the market for the manufacturers and suppliers.

Browse Related Reports:

Ligand Binding Assay Market:  

https://www.marketinsightsreports.com/reports/07083061019/global-ligand-binding-assay-market-size-status-and-forecast-2021-2027?source=Openpr&Mode=Twelve                                         

Programmed Death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market:

https://www.marketinsightsreports.com/reports/08042200774/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market-insights-epidemiology-and-market-forecast-2030?source=Openpr&Mode=Twelve                                             

CD40 Agonist Market:

https://www.marketinsightsreports.com/reports/09252312594/cd40-agonist-pipeline-insight-2020?source=Openpr&Mode=Twelve                                      

Customization Of The Report:

MarketInsightsReports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.     

If you have any questions about any of our “CD40 Ligand market report” or would like to schedule a personalized free demo of CD40 Ligand market report, please do not hesitate to contact me at irfan@marketinsightsreports.com.

Best wishes,

Irfan Tamboli

Head of Sales Operations

Market Insights Reports

Tel: + 1704 266 3234 | +91-750-707-8687

Email: sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.